Dean Li

Dean Li

Founder at RECURSION PHARMACEUTICALS, INC.

Net worth: 23 M $ as of 29/06/2025

61 year
Health Technology
Consumer Services
Commercial Services

News on Dean Li

Merck & Co., Inc., Verona Pharma plc - M&A Call 07-09
Merck & Co., Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 10:00 AM 06-10
U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season 06-09 BU
Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia 06-09 BU
Merck to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference 06-04 BU
Merck & Co., Inc. Presents at American Society of Clinical Oncology Annual Meeting 2025, Jun-02-2025 06:00 PM 06-03
Merck & Co., Inc. Presents at Bernstein 41st Annual Strategic Decisions Conference 2025, May-29-2025 03:30 PM 05-30
Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference 05-22 BU
Merck & Co., Inc., Q1 2025 Earnings Call, Apr 24, 2025 04-24
Merck : 1Q25 Merck Earnings Presentation 04-24 PU
Merck Strikes Nearly $2 Billion Licensing Deal For Chinese Firm's Heart Disease Drug Candidate 03-25 MT
Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd. 03-25 BU
Recursion Pharmaceuticals, Inc. Announces Changes to Committees 03-18 CI
Merck & Co., Inc. Presents at TD Cowen 45th Annual Healthcare Conference, Mar-03-2025 02:30 PM 03-03
Merck to Participate in the TD Cowen 45th Annual Health Care Conference 02-24 BU
Merck & Co., Inc., Q4 2024 Earnings Call, Feb 04, 2025 02-04
Merck : 4Q24 Merck Earnings Presentation 02-04 PU
Merck & Co., Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 04:30 PM 01-14
Recursion Pharmaceuticals, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 07:30 AM 01-13
Merck to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 01-06 BU
Merck Strikes Deal With China's Hansoh Pharma to Develop Weight Loss Drug 12-18 MT
Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist 12-18 BU
Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd. 11-14 BU
Merck & Co., Inc., Q3 2024 Earnings Call, Oct 31, 2024 31/10/24
Merck : 3Q24 Merck Earnings Presentation 31/10/24 PU
Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical 01/10/24 BU
Merck & Co., Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 02:35 PM 05/09/24
Merck to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference 29/08/24 BU
Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical 12/08/24 AQ
Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical 09/08/24 BU
Daiichi Sankyo and Merck & Co., Inc., Rahway, NJ, USA Enter into Global Development and Commercialization Agreement for MK-6070 07/08/24 AQ
Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070 06/08/24 BU
Merck & Co., Inc., Q2 2024 Earnings Call, Jul 30, 2024 30/07/24
Merck Completes Acquisition of EyeBio 15/07/24 AQ
Merck Completes Acquisition of EyeBio 12/07/24 BU
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer 01/07/24 BU
Merck - U.S. FDA Approves CAPVAXIVE for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults 18/06/24 AQ
U.S. FDA Approves CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults 17/06/24 BU
Merck & Co., Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 10:00 AM 11/06/24
Merck to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference 05/06/24 BU
Merck & Co., Inc. Presents at 2024 American Society of Clinical Oncology Annual Meeting, Jun-03-2024 06:00 PM 04/06/24
Merck to Acquire EyeBio 29/05/24 BU
Merck & Co., Inc., Q1 2024 Earnings Call, Apr 25, 2024 25/04/24
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer 16/04/24 GL
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer 16/04/24 AQ
Merck Completes Acquisition of Harpoon Therapeutics, Inc. 11/03/24 BU
Merck & Co. Insider Sold Shares Worth $1,845,083, According to a Recent SEC Filing 12/02/24 MT
Merck & Co., Inc., Q4 2023 Earnings Call, Feb 01, 2024 01/02/24
Recursion Pharmaceuticals Insider Sold Shares Worth $396,214, According to a Recent SEC Filing 12/01/24 MT
Merck & Co., Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 04:30 PM 09/01/24

Linked companies

Listed companies2
RECURSION PHARMACEUTICALS, INC.

Health Technology

MERCK & CO., INC.

Health Technology

Private companies7

Commercial Services

Health Technology

Health Technology

Health Technology

Health Technology

Commercial Services

The University of Utah Health Sciences Center

See company connections

Training of Dean Li

The University of Chicago
Undergraduate Degree
Washington University School of Medicine
Doctorate Degree